Allon granted U.S. patent for neurotoxicity caused by anti-cancer drugs
Dr. Alistair Stewart, Allon’s Vice President of Commercial Research, said the Company’s research has shown that its drug candidates are active in preclinical models of peripheral neuropathy, including neurotoxicity and neuropathic pain associated with anti-cancer therapy. “These data lead us to conclude that AL-309 may have the potential to prevent or reduce neurotoxicity when administered in combination with anti-cancer agents known to cause peripheral neurotoxicity and neuropathic pain,” Stewart said.
Allon previously presented preclinical data at a Society for Neurosciences meeting that showed the activity of AL-309 in chemotherapy-induced neuropathy. AL-309, administered in combination with oxaliplatin (an anti-cancer agent) reduced pain symptoms in a model of peripheral neuropathy.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.